research Implementing Outpatient Screening of Adult Patients at High Risk for Peripheral Artery Disease
Integrating ABI screening in clinics can improve patient care for those at risk of peripheral artery disease.
Search
for
Sort by
Research
60-90 / 1000+ results
research Groundnut seed production manual.
Arsenic trioxide effectively treats APL, improving survival rates despite its toxicity.
research A Hero Revealed: Targeting the AHR for treatment of inflammatory skin diseases
AHR ligands could treat inflammatory skin diseases.
research A Single-Arm, Open-Label, Phase Ib Clinical Study Evaluating the Efficacy and Safety of Durvalumab in Combination with Albumin-Bound Paclitaxel and Carboplatin as Neoadjuvant Therapy for Resectable Stage III Non-Small Cell Lung Cancer
The treatment showed high response rates and was well-tolerated, potentially extending patient survival.
research Synthesis and structure–activity studies of side-chain derivatized arylhydantoins for investigation as androgen receptor radioligands
The nature of the side chain in RU 58841 derivatives greatly affects its AR affinity, with the N-(iodopropenyl) derivative 13 showing the highest AR binding affinity, suggesting its potential for developing high-affinity radioiodinated AR radioligands.
research 5PSQ-117 Effectiveness of baricitinib in alopecia areata
Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.
research Lower prostate cancer risk in Swedish men with the androgen receptor E213 A-allele
Swedish men with the E213 A-allele of the androgen receptor have a lower risk of prostate cancer.
research Efficacité à long terme du baricitinib dans le traitement de la pelade : résultats à la semaine 104 des études BRAVE-AA1 et BRAVE-AA2
Baricitinib effectively treats severe alopecia for up to 104 weeks.
research 202 Activation of breast cancer cell proliferation by ROR-alpha through aromatase promoter
ROR-alpha may increase the growth of certain breast cancer cells by boosting aromatase, which could affect breast cancer prognosis.
research Single‐center study to determine the safety and efficacy of CT‐707 in Chinese patients with advanced anaplastic lymphoma kinase‐rearranged non‐small‐cell lung cancer
CT-707 is effective and safe for treating certain Chinese lung cancer patients.
research Baricitinib: Exploring the Safety Profile for the Treatment of Alopecia Areata
Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.
research Dermoscopic findings in scalp psoriasis and seborrheic dermatitis; Two new signs; Signet ring vessel and hidden hair
Two new signs, 'signet ring vessels' and 'hidden hairs,' help tell apart scalp psoriasis and seborrheic dermatitis.
research Crosstalk between vimentin and keratins in viral infection: Implications across the viral life cycle
Vimentin and keratin help viruses spread and could be targets for antiviral treatments.
research Abstract P5-09-21: Selective androgen receptor modulators (SARMs): Enobosarm as targeted therapy for the treatment of androgen receptor-positive breast cancer
Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.
research Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
research 706 Predictive modeling of patient response to JAK/STAT inhibitors and dynamic patient-matching
Machine learning can predict how well patients with alopecia areata will respond to certain treatments.
research A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma – the DUCT study protocol
Adding dutasteride to therapy may improve treatment for advanced salivary duct cancer.
research Giant axonal neuropathy alters the structure of keratin intermediate filaments in human hair
Giant axonal neuropathy changes the structure of keratin in human hair.
research Strong efficacy of ritlecitinib 50 mg and baricitinib 4 mg in alopecia areata, but further research needed to establish superiority
Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
research Generic vs. Disease-Specific Patient Reported Outcome (PRO) Instruments for Assessing HRQoL Burden Among Patients Diagnosed with Alopecia Areata: Evidence from TARGET-DERM AA
Disease-specific tools better assess quality of life in alopecia areata patients.
research The safety profiles of avacopan on microscopic polyangiitis and granulomatosis with polyangiitis: a real-world pharmacovigilance analysis
Avacopan is generally safe, with some minor side effects like nausea and fatigue.
research Supplementary Material for: Patient Preferences: Results of a German Adaptive Choice-Based Conjoint Analysis (Market Research Study Sponsored by Eli Lilly and Company) in Patients on Palliative Treatment for Advanced Breast Cancer
Patients with advanced breast cancer prioritize quality of life, overall survival, and progression-free survival in treatment decisions.
research Budget impact analysis of baricitinib for treatment of alopecia areata: A Saudi hospital perspective
Adding baricitinib will increase costs but offers more treatment options for alopecia areata.
research Hereditary vitamin D-resistant rickets (HVDRR) owing to a heterozygous mutation in the vitamin D receptor
A girl had rickets due to a gene mutation affecting vitamin D response.
research Abstract PS1-01-19: Exploratory Study on the Efficacy and Safety of Combined Scalp Cooling and HairRepro MEDIα for Chemotherapy-Induced Alopecia in Japanese Breast Cancer Patients
The combined treatment helped prevent hair loss and promoted full hair regrowth in breast cancer patients after chemotherapy.
research 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials
Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
research Supplementary Material for: Patient Preferences: Results of a German Adaptive Choice-Based Conjoint Analysis (Market Research Study Sponsored by Eli Lilly and Company) in Patients on Palliative Treatment for Advanced Breast Cancer
Quality of life, overall survival, and progression-free survival should be equally prioritized in advanced breast cancer treatment decisions.
research Abstract ED05-04: Presurgical models to effectively screen preventive agents
Presurgical models can effectively and affordably screen cancer prevention agents.
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
research Reproduction of the human relevant potency threshold (HRPT) for estrogen receptor alpha agonism in an inference performance screen for ICCVAM’s regulatory scientific confidence framework
A new method effectively predicts estrogen-related health effects for early screening.